News

Deal Announcements

ORIC Pharma Clears Series B Funding

Friday, December 4, 2015 5:40:00 AM PDT | VentureDeal
   South San Francisco, California  --  ORIC Pharmaceuticals announce that it has received $53 million in second round institutional venture capital commitments.

ORIC is developing novel therapies for treatment-resistant cancers.

For example, the company cited that despite therapeutic advances, an estimated 27,540 men will die of hormone-refractory prostate cancer due to relapse.

Investors in the financing included The Column Group, Topspin Partners, OrbiMed, EcoR1 Capital Management, Foresite Capital and others.

The company said it would use the funding to support the advancement of its first drug candidate as well as further develop its pipeline.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1